COVID Articles
Much remains to be learned about this new condition affecting a growing number of children. However, it is hoped with increased vaccination and fewer cases of the SARS-CoV-2 virus, case numbers of MIS-C will also go down.
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
With three vaccines in circulation and three more on the horizon, is the end of the COVID-19 pandemic in sight?
Long-haul COVID, now termed PASC, is a very real effect of the SARs-CoV-2 virus, but few physicians are familiar with the symptoms and where to send patients for treatment.
After several federal agencies spent two decades and tens of billions of dollars preparing for the next pandemic, critics were not shy about pointing out how unprepared the United States was for the current SARS-Cov-2 pandemic.
As of this writing, NIAID and industry collaborators are also finalizing the design of a large-scale trial to assess whether COVID-Ig can reduce the rate of hospitalization and other medical encounters in earlier-stage COVID-19 patients exhibiting mild to moderate symptoms.
Studies shed light on whether high-dose intravenous immune globulin, convalescent plasma and hyperimmune globulin will be effective therapeutic options for the novel coronavirus.
Social media platforms have given the anti-vaccine faction a significant voice that has undermined advances in public health. Now, in the wake of a global pandemic, healthcare stakeholders may have an opportunity to reclaim the narrative about vaccines with facts, not fiction.
As governments around the world ramp up COVID-19 prevention activities, are other diseases of international importance and their prevention programs suddenly on pause?
